NeOnc Technologies appoints Dr. Josh Neman as Chief Clinical Officer to enhance clinical trials and drug delivery innovations.
Quiver AI Summary
NeOnc Technologies Holdings, Inc. has appointed Dr. Josh Neman as Chief Clinical Officer to enhance its clinical development strategy for innovative treatments targeting central nervous system cancers. Dr. Neman, a prominent figure in neurooncology and brain tumor research with a background at USC, will lead NeOnc's clinical trials, including the promising NEO100, which is nearing the completion of its Phase 2a trial ahead of schedule. His role involves expanding partnerships with academic institutions, regulatory bodies, and patient advocacy groups, while NeOnc aims to integrate AI and quantum computing into its drug delivery platform. This appointment is seen as a pivotal move toward achieving FDA approval and transforming cancer treatment outcomes.
Potential Positives
- Appointment of Dr. Josh Neman as Chief Clinical Officer enhances leadership and expertise in clinical development.
- Completion of Phase 2a trial for lead asset NEO100 ahead of schedule demonstrates significant progress in clinical trials.
- Dr. Neman's background and recognition in neurooncological sciences could strengthen research collaborations and partnerships.
- Integration of AI and quantum computing into the drug delivery platform may improve therapeutic outcomes and drive innovation.
Potential Negatives
- The reliance on forward-looking statements may raise concerns among investors about the company's ability to achieve its projected milestones and outcomes, increasing uncertainty regarding future performance.
- The company's exploration of integrating AI and quantum computing into its drug delivery platform may be perceived as speculative and could divert focus from more traditional therapeutic advancements.
- The appointment of a new Chief Clinical Officer, while presented positively, may indicate internal organizational changes that could disrupt ongoing clinical development and strategic initiatives.
FAQ
What is NeOnc Technologies Holdings, Inc. focused on?
NeOnc Technologies is focused on developing innovative treatments for central nervous system cancers and disorders.
Who is the new Chief Clinical Officer at NeOnc?
Dr. Josh Neman has been appointed as the new Chief Clinical Officer at NeOnc Technologies Holdings, Inc.
What major clinical trials are underway at NeOnc?
NeOnc is accelerating four clinical trials, including their lead asset NEO100, which is nearing Phase 2a completion.
How does Dr. Neman's background benefit NeOnc?
Dr. Neman's expertise in neurooncological sciences will help advance NeOnc’s clinical development strategy and FDA approval efforts.
What technologies is NeOnc exploring for drug delivery?
NeOnc is exploring the integration of AI and quantum computing to enhance its drug delivery platform.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NTHI Insider Trading Activity
$NTHI insiders have traded $NTHI stock on the open market 16 times in the past 6 months. Of those trades, 16 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NTHI stock by insiders over the last 6 months:
- AMIR F HESHMATPOUR (President) has made 7 purchases buying 12,000 shares for an estimated $121,299 and 0 sales.
- THOMAS C CHEN (CEO) has made 3 purchases buying 5,868 shares for an estimated $42,802 and 0 sales.
- JIM DELSHAD has made 3 purchases buying 5,100 shares for an estimated $37,258 and 0 sales.
- KEITHLY GARNETT (CFO) has made 3 purchases buying 900 shares for an estimated $6,527 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule
Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform
CALABASAS, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational research, and academic medicine.
Dr. Neman joins NeOnc Technologies Holdings Inc. (NeOnc) from the Keck School of Medicine at the University of Southern California (USC), where he serves as Associate Professor of Neurological Surgery and Physiology & Neuroscience, and Scientific Director of the USC Brain Tumor Center. At USC, he also leads the Cancer Biology and Genomics PhD Program and serves as Director of Cancer Research Training and Education Coordination at the USC Norris Comprehensive Cancer Center- a leading National Cancer Institute-designated cancer research hospital.
A nationally recognized leader in neurooncological sciences and cancer neuroscience, Dr. Neman’s research has advanced the understanding of how brain microenvironments influence the progression of brain tumors and metastases. His pioneering studies on tumor-neuron interactions, GABAergic signaling in cancer, and mechanisms of leptomeningeal dissemination have helped shape new therapeutic paradigms for both adult and pediatric brain tumors.
“I am deeply honored to join NeOnc at this exciting time,” said Dr. Neman. “NeOnc’s commitment to developing innovative therapeutics, including Blood Brain Barrier-penetrant compounds like NEO212 and NEO100, aligns perfectly with my lifelong passion to improve outcomes for patients with brain tumors. I look forward to helping lead the translation of promising discoveries from the lab into meaningful clinical impact.”
In his role as Chief Clinical Officer, Dr. Neman will lead NeOnc’s clinical development strategy, including investigator-initiated trials and precision oncology partnerships. He will also play a key role in expanding NeOnc’s research collaborations with academic institutions, regulatory agencies, and patient advocacy groups.
“Dr. Neman’s appointment signals a major step forward in NeOnc’s mission to transform the treatment landscape for patients with life-threatening cancers with poor outcomes,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, Inc. “His academic and clinical leadership, coupled with his deep expertise in brain tumor biology, will be instrumental in accelerating all four of our clinical trials—especially our lead asset, NEO100, which is approaching the completion of its Phase 2a trial with full enrollment achieved ahead of schedule. As we look to add AI and quantum computing into our expanding platform in drug delivery and bio-conjugation, Dr. Neman’s appointment further strengthens our commitment to advancing precision therapies and driving toward FDA approval.”
About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI):
NeOnc Technologies is a publicly traded, clinical-stage biopharmaceutical company developing innovative therapies for brain and central nervous system cancers. Its lead programs—NEO100-01, NEO100-02, NEO100-03, and NEO212—utilize proprietary formulations to bypass the blood-brain barrier and target malignancies with precision. The company’s IP portfolio includes 176 patents worldwide, reflecting a broad platform with strong commercialization potential.
For more about NeOnc and its pioneering technology, visit neonc.com .
Important Cautions Regarding Forward-Looking Statements
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate," or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law. “NEO100” is a registered trademark of NeOnc Technologies Holdings, Inc.
Company Contact:
23975 Sorrento Park
Suite 205,
Calabasas, CA, 91302
[email protected]
Investor Relations:
James Carbonara
Hayden IR
369 Lexington Avenue
Second Floor
New York, NY 10017
Office: (646)-755-7412
[email protected]
www.haydenir.com
